For patients with advanced and or unresectable non-small cell lung cancer (NSCLC) who do not fit an approved molecular targeted therapy (e.g., KRAS wild-type), treatment options include regimens of radiotherapy and platinum-based chemotherapy, with or without immune therapy [4]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.